Literature DB >> 26487055

Immune checkpoint inhibitors: a new frontier in bladder cancer.

Max Kates1,2, Nikolai A Sopko3,4, Hotaka Matsui3,4, Charles G Drake3,4, Noah M Hahn3,4, Trinity J Bivalacqua3,4.   

Abstract

Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.

Entities:  

Keywords:  Bladder cancer; Immune checkpoint; Tumor immunology

Mesh：

Substances：

Year:  2015        PMID： 26487055     DOI： 10.1007/s00345-015-1709-y

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  63 in total

1.  Radiotherapy complements immune checkpoint blockade.

Authors:  Shin Foong Ngiow; Grant A McArthur; Mark J Smyth
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 3.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Authors:  Claire Vanpouille-Box; Karsten A Pilones; Erik Wennerberg; Silvia C Formenti; Sandra Demaria
Journal:  Vaccine       Date:  2015-07-03       Impact factor: 3.641

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 6.  Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Authors:  Mario P Colombo; Silvia Piconese
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 7.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

8.  Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.

Authors:  Teppei Sonoda; Kazunobu Sugimura; Shin-Ichi Ikemoto; Hidenori Kawashima; Tatsuya Nakatani
Journal:  Oncol Rep       Date:  2007-06       Impact factor: 3.906

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307
View more
  7 in total

1.  Evolving concepts in muscle-invasive bladder cancer.

Authors:  Peter C Black; Wassim Kassouf
Journal:  World J Urol       Date:  2016-01       Impact factor: 4.226

2.  B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway.

Authors:  Yuchao Li; Guoning Guo; Jie Song; Zhiping Cai; Jin Yang; Zhiwen Chen; Yun Wang; Yaqin Huang; Qiangguo Gao
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

3.  Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.

Authors:  Wei Chen; Jiancheng Zhou; Kaijie Wu; Jun Huang; Ye Ding; Eun-Jin Yun; Bin Wang; Chunyong Ding; Elizabeth Hernandez; John Santoyo; Haiying Chen; Ho Lin; Arthur Sagalowsky; Dalin He; Jia Zhou; Jer-Tsong Hsieh
Journal:  Oncotarget       Date:  2016-08-30

Review 4.  Current status and future directions of cancer immunotherapy.

Authors:  Hongming Zhang; Jibei Chen
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

5.  Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial.

Authors:  Hyeong Dong Yuk; Chang Wook Jeong; Cheol Kwak; Hyeon Kim; Kyung Chul Moon; Ja Hyeon Ku
Journal:  BMJ Open       Date:  2020-10-15       Impact factor: 2.692

6.  Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.

Authors:  Mihai Dorin Vartolomei; Romain Mathieu; Vitaly Margulis; Jose A Karam; Morgan Rouprêt; Ilaria Lucca; Aurélie Mbeutcha; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Christopher G Wood; Alon Z Weizer; Jay D Raman; Nathalie Rioux-Leclercq; Andrea Haitel; Karim Bensalah; Michael Rink; Alberto Briganti; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-05-21       Impact factor: 4.226

Review 7.  Immune checkpoint inhibitors for urothelial carcinoma.

Authors:  Hyung Suk Kim; Ho Kyung Seo
Journal:  Investig Clin Urol       Date:  2018-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.